Advertisement

Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure

  • Michael Aviram
    Correspondence
    Corresponding author. Tel.: +972-4-8542970; fax: +972-4-8542130
    Affiliations
    The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, 31096 Haifa, Israel
    Search for articles by this author
  • Leslie Dornfeld
    Affiliations
    The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, 31096 Haifa, Israel
    Search for articles by this author

      Abstract

      Consumption of pomegranate juice which is rich in tannins, possess anti-atherosclerotic properties which could be related to its potent anti-oxidative characteristics. As some antioxidants were recently shown to reduce blood pressure, we studied the effect of pomegranate juice consumption (50 ml, 1.5mmol of total polyphenols per day, for 2 weeks) by hypertensive patients on their blood pressure and on serum angiotensin converting enzyme (ACE) activity. A 36% decrement in serum ACE activity and a 5% reduction in systolic blood pressure were noted. Similar dose-dependent inhibitory effect (31%) of pomegranate juice on serum ACE activity was observed also in vitro. As reduction in serum ACE activity, even with no decrement in blood pressure, was previously shown to attenuate atherosclerosis, pomegranate juice can offer a wide protection against cardiovascular diseases which could be related to its inhibitory effect on oxidative stress and on serum ACE activity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Langley P.
        Why a pomegranate?.
        BMJ. 2000; 321: 1153-1154
        • Narr Ben C.
        • Ayed N.
        • Metche M.
        Quantitative determination of the polyphenolic content of pomegranate peel.
        Z Lebensm Unters Forsch. 1996; 203: 374-378
      1. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kedar AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing, J Agric Food Chem 2000;10:4581–9.

        • Aviram M.
        • Dorenfeld L.
        • Rosenblat M.
        • Volkova N.
        • Kaplan M.
        • Hayek T.
        • et al.
        Pomegranate juice consumption reduces oxidative stress, low density lipoprotein modifications and platelet aggregation: studies in the atherosclerotic apolipoprotein E deficient mice and in humans.
        Am J Clin Nutr. 2000; 71: 1062-1076
        • Aviram M.
        Does paraoxonase play a role in susceptibility to cardiovascular disease?.
        Mol Med Today. 1999; 5: 381-386
        • Alderman H.H.
        • Madhavan S.
        • Ooi W.L.
        • Cohen H.
        • Sealey J.E.
        • Laragh J.H.
        Association of the rennin–sodium profile with the risk of myocardial infarction in patients with hypertension.
        N Engl J Med. 1991; 324: 1098-1111
        • Pfeffer M.A.
        • Branuwald E.
        • Moye L.A.
        Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 1992; 327: 669-676
        • Colins R.
        • Peto R.
        • MacMahon S.
        • Hebert P.
        • Fiebach N.H.
        • Eberlein K.A.
        • et al.
        Blood pressure, stroke and coronary heart disease. Short-term reduction in blood pressure: overview of randomized drug trials epidemiological content.
        Lancet. 1990; 335: 827-838
        • Dzau V.J.
        Circulating versus local renin-angiotensin system in cardiovascular homeostasis.
        Circulation. 1988; 77: 14-21
        • Griendling K.K.
        • Tsuda T.
        • Berk B.C.
        • Alexander R.W.
        Angiotensin II stimulation of vascular smooth muscle cells.
        J Cardiovasc Pharmacol. 1989; 14: S27-S33
        • Keidar S.
        • Kaplan M.
        • Shapira H.
        • Brook J.G.
        • Aviram M.
        Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II.
        Atherosclerosis. 1994; 107: 71-84
        • Kowala M.
        • Grove R.
        • Aberg G.
        Inhibitors of angiotensin-converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids.
        Atherosclerosis. 1994; 108: 61-72
        • Chobanian A.
        • Handenschild C.
        • Nickerson C.
        • Drago R.
        Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.
        Hypertension. 1990; 15: 327-331
        • Rolland P.H.
        • Souchet T.
        • Friggi A.
        Angiotensin converting enzyme inhibition-induced changes in patterns of hemodynamics, aorta viscoelasticity, arterial histopathology and endothelial cholesterol fluxes of atherosclerotic minipigs.
        J Hypertens. 1991; 9: S178-S179
        • Duffy S.L.
        • Gocke N.
        • Holbrook M.
        • Huang A.
        • Frei B.
        • Keaney Jr., J.F.
        • et al.
        Treatment of hypertension with ascorbic acid.
        Lancet. 1999; 354: 2048-2049
        • Galley H.F.
        • Thornton J.
        • Howdle P.D.
        • Walker B.E.
        • Webster N.R.
        Combination oral antioxidant supplementation reduces blood pressure.
        Clin Sci. 1997; 92: 361-365
        • Singh R.B.
        • Niaz M.A.
        • Rastogi S.S.
        • Shukla P.K.
        • Thakur A.S.
        Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.
        J Hum Hypertens. 1999; 13: 203-208
        • Narr Ben C.
        • Ayed N.
        • Metche M.
        Quantitative determination of the polyphenolic content of pomegranate peel.
        Z Lebensm Unters Forsch. 1996; 203: 374-378
        • Kitiyakara C.
        • Wilcox C.S.
        Antioxidants for hypertension.
        Curr Opin Nephrol Hypertens. 1998; 7: 531-538
        • He K.
        • Lyer K.R.
        • Hayes R.N.
        Inactivation of cytochrome P-450 3A4 by bergamottin, a component of grapefruit juice.
        Chem Res Toxicol. 1998; 11: 252-259
        • Keidar S.
        • Attias J.
        • Coleman R.
        • Wirth K.
        • Scholkens B.
        • Hayek T.
        Attenuation of atherosclerosis in apolipoprotein E deficient mice Ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin.
        J Cardiovasc Pharmacol. 2000; 35: 64-72
        • Scheen A.J.
        The HOPE study: demons the cardiovascular protection of Ramipril, a ACE inhibitor.
        Rev Med Liege. 1999; 54: 835-836